7
Business Forum Partnering Doing it right Therapeutic Trends in Deals – BIO top 10

Therapeutic Trends in Deals – BIOs top 10

Embed Size (px)

DESCRIPTION

This powerpoint gives you insights into the percentage of development/commercialization deals by highest phase at deal start (May 2012 - May 2014)

Citation preview

Page 1: Therapeutic Trends in Deals – BIOs top 10

Business Forum PartneringDoing it right

Therapeutic Trends in Deals – BIO top 10

Page 2: Therapeutic Trends in Deals – BIOs top 10

Deal phases

Source: Thomson Reuters Cortellis

PreClinical Phase 2 Phase 1 unspecified Phase 3 Launched Pre-registration Registered0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

40.0%

45.0%

50.0%

% of development/commercialization deals by highest phase at deal startMay 2012 - May 2014

Page 3: Therapeutic Trends in Deals – BIOs top 10

Preclinical deals

Neopl

asm

Infe

ctio

us d

iseas

e

Neuro

logi

cal d

iseas

e

Gastro

inte

stin

al d

isea

se

Infla

mm

ator

y di

seas

e

Respi

rato

ry d

iseas

e

Imm

une

diso

rder

Metab

olic d

isor

der

Hemat

olog

ical d

isea

se

Endo

crin

e di

seas

e0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

% of pre-clinical development/commercialization deals by therapeutic areaMay 2012 - May 2014

Source: Thomson Reuters Cortellis

Page 4: Therapeutic Trends in Deals – BIOs top 10

Phase 1 deals

Source: Thomson Reuters Cortellis

Neopl

asm

Neuro

logi

cal d

iseas

e

Infe

ctio

us d

iseas

e

Infla

mm

ator

y di

seas

e

Gastro

inte

stin

al d

isea

se

Cardi

ovas

cula

r dise

ase

Respi

rato

ry d

iseas

e

Imm

une

diso

rder

Muscu

losk

elet

al d

isea

se

Degen

erat

ion

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

% of phase 1 development/commercialization deals by therapeutic area May 2012 - May 2014

Page 5: Therapeutic Trends in Deals – BIOs top 10

Phase 2 deals

Source: Thomson Reuters Cortellis

Neopl

asm

Gastro

inte

stin

al d

isea

se

Infe

ctio

us d

iseas

e

Infla

mm

ator

y di

seas

e

Neuro

logi

cal d

iseas

e

Imm

une

diso

rder

Derm

atol

ogica

l dise

ase

Respi

rato

ry d

iseas

e

Genito

urin

ary

dise

ase

Gynec

olog

y an

d ob

stet

rics

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

14.0%

16.0%

18.0%

20.0%

% of phase 2 development/commercialization deals by therapeutic areaMay 2012 - May 2014

Page 6: Therapeutic Trends in Deals – BIOs top 10

Phase 3 deals

Source: Thomson Reuters Cortellis

Gastro

inte

stin

al d

isea

se

Neopl

asm

Infe

ctio

us d

iseas

e

Hemat

olog

ical d

isea

se

Neuro

logi

cal d

iseas

e

Endo

crin

e di

seas

e

Cardi

ovas

cula

r dise

ase

Metab

olic d

isor

der

Infla

mm

ator

y di

seas

e

Respi

rato

ry d

iseas

e0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

% of phase 3 development/commercialization deals by therapeutic areaMay 2012 - May 2014

Page 7: Therapeutic Trends in Deals – BIOs top 10

#BIO2014

convention.bio.org